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Abstract 
Objective  To examine associations between cardiovascular system medication use with cognition function and diagnosis of dementia 
in older adults living in nursing homes in Australia. Methods  As part of a cross-sectional study of 17 Australian nursing homes examining 
quality of life and resource use, we examined the association between cognitive impairment and cardiovascular medication use (identified 
using the Anatomical Therapeutic Classification System) using general linear regression and logistic regression models. People who were 
receiving end of life care were excluded. Results  Participants included 541 residents with a mean age of 85.5 years (± 8.5), a mean Psy-
chogeriatric Assessment Scale–Cognitive Impairment (PAS-Cog) score of 13.3 (± 7.7), a prevalence of cardiovascular diseases of 44% and 
of hypertension of 47%. Sixty-four percent of participants had been diagnosed with dementia and 72% had received cardiovascular system 
medications within the previous 12 months. Regression models demonstrated the use of cardiovascular medications was associated with 
lower (better) PAS-Cog scores [Coefficient (β) = 3.7; 95% CI: 5.2 to 2.2; P < 0.0001] and a lower probability of a dementia diagnosis 
(OR = 0.44; 95% CI: 0.26 to 0.75, P = 0.0022). Analysis by subgroups of medications showed cardiac therapy medications (C01), beta 
blocking agents (C07), and renin-angiotensin system agents (C09) were associated with lower PAS-Cog scores (better cognition) and lower 
dementia diagnosis probability. Conclusions  This analysis has demonstrated an association between greater cardiovascular system medica-
tion use and better cognitive status among older adults living in nursing homes. In this population, there may be differential access to health 
care and treatment of cardiovascular risk factors. This association warrants further investigation in large cohort studies. 
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1  Introduction 
Dementia is a condition that has a number of causes, 
most commonly Alzheimer’s disease, and is characterised 
by a gradual decline in cognitive function. Cognitive func-
tions that may be affected include memory, orientation, 
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learning, problem-solving, attention, language and the abil-
ity to perform activities of daily living.[1] It has been esti-
mated that worldwide there are 47 million people living 
with dementia and the number of people living with demen-
tia is expected to be more than 131 million by 2050 and the 
total estimated cost of dementia is about $US818 billion in 
2015.[2]  
Whilst Alzheimer’s disease is the most common type of 
dementia, there is increasing awareness that dementia of 
mixed pathology is more common than dementia of discrete 
types.[3] Neurodegeneration and cerebrovascular damage to 
the brain are the two main causes of age-related cognitive 
decline and dementia.[4–6] Cardiovascular and cerebrovascu-
lar diseases share many pathophysiological traits and risk 
factors and even heart disease itself could be a risk factor for 
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dementia.[7–10] Many classes of cardiovascular drugs have 
demonstrated effectiveness in the primary prevention, acute 
treatment and secondary prevention of stroke which is a risk 
factor for cognitive impairment and dementia.[11] In addition, 
in some trials of cardiovascular medications a protective 
effect against cognitive decline and dementia has been 
demonstrated, in particular with lipid lowering agents, al-
though findings are inconsistent.[12–18] People in nursing 
homes have high prevalence of cardiovascular disease 
(CVD) risk factors and high use of CVD mediations.[19] For 
these reasons, the high rate of use of these medications in 
aged care may have associations with cognitive status. 
There is often a lengthy delay between the appearance of 
symptoms of dementia and it’s diagnosis.[20] Diagnosis is 
based upon clinical criteria following assessment of the pa-
tient’s history, cognitive and mental state assessment, 
physical examination and medication review.[21] A large 
proportion of dementia is undetected in community and 
institutional settings and it is estimated that approximately 
half of people living with dementia in nursing homes are not 
diagnosed.[22] In Australian nursing home settings, cognitive 
function is routinely assessed using the Psychogeriatric As-
sessment Scale–Cognitive Impairment (PAS-Cog) instru-
ment.[23] The PAS-Cog consists of nine questions to test the 
subject’s memory and other cognitive functions, with higher 
scores indicating greater impairment. The aim of this analy-
sis is to examine associations of cardiovascular system 
medications with cognitive function and diagnosis of de-
mentia in older adults living in nursing homes in Australia. 
2  Methods 
2.1  Design, settings and participants 
The Investigating Services Provided in the Residential 
Environment for Dementia (INSPIRED) Study is a cross- 
sectional study designed to determine and compare the 
quality of life, quality of care, utilisation of healthcare re-
sources and costs of various residential care facilities that 
provide alternative models of dementia care for people with 
cognitive impairment and dementia. We collected data from 
17 not-for profit nursing homes across 4 Australian states 
between January 2015 and February 2016. The inclusion 
criteria for INSPIRED were: (1) being permanent residents 
of the facility; (2) residing in the facility for 12 months or 
more; (3) not in immediate palliative care; (4) if not able to 
self-consent, have family who are able to provide proxy 
consent and/or participate on the resident’s behalf; and (5) 
no other complex medical or family issues that would pre-
vent participation. Written informed consents were obtained 
from participants or their legal guardians. Ethics approval 
for the study was obtained from the Flinders University 
social and behavioural research ethics committee. As part of 
this study we collected comprehensive data on medication 
use.  
2.2  Cognitive and comorbidities measures 
We collected the most recent (within three months) PAS- 
Cog scale data from nursing home records. If a participant 
had a PAS-Cog score older than three months and that score 
was higher than 18 (of a possible 21) points we retained that 
score as the most recent score based on an assumption that 
an additional PAS-Cog score would not substantially im-
prove. If there was a PAS-Cog score older than three 
months but less than 18 points, a trained research nurse 
conducted a face-to-face interview to obtain the PAS-Cog 
data. A diagnosis of dementia was collected from the resi-
dential facility’s medical records. In Australia, the Aged 
Care Act 1997 requires that all nursing homes must keep 
records about a resident’s medical conditions, the treatment 
they are receiving and the type of care that is being provided 
under a resident’s care plan.[24] Data on participants’ comor-
bidities were also collected from residential facility medical 
records. 
2.3  Cardiovascular medication use 
The exposure variable for this analysis was whether a 
subject had been using medications active on the cardio-
vascular system within the last 12 months. We classified 
medication use according to the Anatomical Therapeutic 
Chemical (ATC) classification system.[25] Cardiovascular 
(C-class) medications that are considered predominantly to 
be used to manage cardiovascular risk factors were exam-
ined. Cardiovascular system medications are coded as fol-
lows: C01: cardiac therapy (cardiac glycosides, antiar-
rhythmics and vasodilators and other preparations used in 
cardiac diseases), C02: antihypertensives (antiadrenergics, 
agents acting on areolar smooth muscle), C03: diuretics, 
C04: peripheral vasodilators, C05: vasoprotective agents, 
C07: beta blocking agents, C08: calcium channel blockers, 
C09: agents acting on the renin-angiotensin system and C10: 
lipid modifying agents.[25]  
Medication use information was obtained from three 
possible sources: (1) Pharmaceutical Benefits Scheme (PBS) 
data,[26] with the federal Department of Human Services of 
Australia providing details of the service records for con-
senting participants; (2) Pharmacy data records from 
nursing home-contracted pharmacists, or (3) Facility-based 
medication charts when pharmacy data could not be ob-
tained. 
For this analysis a participant was considered to have 
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been exposed if they had been prescribed cardiovascular 
system medications at any point during the previous 12 
months. 
2.4  Statistical methods 
Means, standard deviations and percentages were used to 
describe the sample. Analysis of variance (ANOVA), 
Chi-square test and Fisher exact test were used to compare 
the means and proportions across PAS-Cog categories cor-
responding to no (score 0 to 4), mild (score 5 to 9), moder-
ate (score 10 to 15) or severe (score 16 to 21) cognitive im-
pairment and whether or not participants had a dementia 
diagnosis. We used general linear regression models to test 
the associations between cognitive impairment (measured 
by the continuous PAS-Cog score) and cardiovascular 
medications. Logistic regression models were used to test 
associations between diagnosis of dementia (yes vs. no) and 
cardiovascular medications. Unadjusted analyses were ini-
tially conducted and adjusted analyses controlling for poten-
tial confounding factors were performed. For multivariable 
general linear regression and multivariable logistic regres-
sion, adjustments were made for residents’ age and gender, 
comorbidities related to cognition, dementia and cardiovas-
cular disease, total number of comorbidities and the use of 
agents predominantly used for secondary prevention of car-
diovascular disease, i.e. antithrombotic agents (B01) and 
antihemorrhagics (B02). Further analysis to investigate as-
sociations between the subgroups of the cardiovascular sys-
tem medications and cognitive impairment and dementia 
were also performed using the same models. 
3  Results 
In total, 1323 residents from the facilities were assessed 
and 901 were eligible to participate, of these 541 consented 
to be part of the INSPIRED study. The mean age was 85.5 
years (± 8.5); 74.5% were female; the average PAS-Cog 
score was 13.3 (± 7.7); 83% (448) of the participants had 
some level of cognitive impairment based on the PAS-Cog 
score, and 64.6% had been diagnosed with dementia. There 
was a high prevalence of cardiovascular disease in the study 
sample; 44% had a history of cardiovascular disease (in-
cluding angina, congestive cardiac failure, atrial fibrillation, 
ischaemic heart disease, or stroke) and 47% a history of 
hypertension (Table 1). Seventy-two percent (390) of the 
participants had been prescribed medications acting on the 
cardiovascular system during the previous 12 months. Table 
1 summarises the use of individual classes of medications. 
Table 2 and Table 3 summarise the distributions of consid-
ered covariates according to PAS-Cog score and dementia  
Table 1.  Characteristics of INSPIRED study sample. 
Characteristic 
Total sample 
size (n = 541)
Age, yrs 85.5 ± 8.5 
Female 403 (74.5%)
Cardiovascular disease history* 239 (44.2%)
Hypertension history 254 (47.1%)
Hypercholesterolemia history 120 (22.3%)
DVT history 5 (0.93%) 
PAS-Cog score 13.3 ± 7.7 
PAS-Cog score 0–4, no cognitive impairment 93 (17.2%) 
PAS-Cog score 5–9, mild cognitive impairment 100 (18.5%)
PAS-Cog score 10–15, moderate cognitive impairment 82 (15.2%) 
PAS-Cog 16–21, severe cognitive impairment 266 (49.2%)
Dementia 348 (64.6%)
Use of any ATC C-class Cardiovascular System Medication 390 (72.1%)
C01 Cardiac therapy 95 (17.6%) 
C02 Antihypertensives 16 (3.0%) 
C03 Diuretics 161 (29.8%)
C04 Peripheral vasodilators 4 (0.74%) 
C05 Vasoprotectives 15 (2.8%) 
C07 Beta blocking agents 114 (21.1%)
C08 Calcium channel blockers 81 (15.0%) 
C09 Agents acting on the renin-angiotensin system 193 (35.7%)
C10 Lipid modifying agents 169 (31.2%)
Other considered drug use  
B01 Antithrombotic agents 131 (24.2%)
B02 Antihemorrhagics 3 (0.56%) 
Data were presented as mean ± SD or n (%). *Including those with a history 
of angina, congestive cardiac failure, atrial fibrillation, ischaemic heart 
disease and stroke. ATC: Anatomical Therapeutic Chemical Classification 
System, DVT: deep vein thrombosis, PAS-Cog: Psychogeriatric Assess-
ment Scale–Cognitive Impairment. 
 
diagnosis. These include ATC code B level 2 medications 
considered likely to be used to treat existing cardiovascular 
disease and comorbidities associated with cardiovascular 
disease and cognition that may confound the analysis. Sig-
nificant differences in the distribution of age, cardiovascular 
medication use, the use of antithrombotic agents, the total 
number of comorbidities and a history of congestive heart 
failure, ischaemic heart disease and cardiovascular disease 
were noted by PAS-Cog category. Significant differences in 
the use of cardiovascular medication use, the use of anti-
thrombotic agents, the total number of comorbidities and a 
medical history of hypertension, congestive heart failure, 
ischaemic heart disease, stroke and diabetes between those 
diagnosed with dementia or not were observed. 
Unadjusted general linear regression models on PAS-Cog 
score and unadjusted logistic regression models on diagnosis 
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Table 2.  Characteristics and comorbidities of study sample by PAS-Cog score. 
No cognitive  
impairment 
Mild cognitive 
impairment 
Moderate cognitive 
impairment 
Severe cognitive 
impairment 
(PAS-Cog 0–4) (PAS-Cog 5–9) (PAS-Cog 10–15) (PAS-Cog 16–21)
Characteristic 
n = 93 n = 93 n = 93 n = 93 
P values 
Age, yrs 85.1 ± 8.6 86.8 ± 8.6 87.3 ± 7.3 84.5 ± 8.7 0.0200 
Female 68 (73.1%) 68 (68.0%) 64 (78.1%) 203 (76.3%) 0.3446 
Any ATC C-class Cardiovascular System Medication 84 (90.3%) 81 (81.0%) 60 (73.2%) 165 (62.0%) < 0.0001 
C01 Cardiac therapy 30 (32.3%) 27 (27.0%) 13 (15.9%) 29 (10.9%) < 0.0001 
C02 Antihypertensives 5 (5.4%) 4 (4.0%) 3 (3.7%) 6 (2.3%) 0.5063 
C03 Diuretics 37 (39.8%) 38 (38.0%) 26 (31.7%) 61 (22.9%) 0.0033 
C04 Peripheral vasodilators 0 (0.0%) 1 (1.0%) 0 (0.0%) 3 (1.1%) 0.5843 
C05 Vasoprotectives 0 (0.0%) 4 (4.0%) 4 (4.9%) 7 (2.6%) 0.2054 
C07 Beta blocking agents 29 (31.2%) 26 (26.0%) 21 (25.6%) 42 (15.8%) 0.0068 
C08 Calcium channel blockers 24 (25.8%) 17 (17.0%) 14 (17.1%) 28 (10.5%) 0.0047 
C09 Agents acting on the renin-angiotensin system 51 (54.8%) 45 (45.0%) 37 (37.8%) 75 (28.2%) < 0.0001 
C10 Lipid modifying agents 44 (47.3%) 32 (32.0%) 27 (32.9%) 74 (27.8%) 0.0077 
ATC B-class Anticoagulant Medications      
B01 Antithrombotic agents 27 (29.03%) 29 (29.0%) 13 (15.9%) 36 (13.5%) 0.0005 
B02 Antihemorrhagics 1 (1.1%) 2 (2.0%) 0 (0.0%) 9 (3.4%) 0.2501 
Comorbidities – medical history      
Hypertension 53 (57.0%) 44 (44.0%) 43 (52.4%) 114 (43.2%) 0.0858 
Hypercholesterolaemia 26 (28.0%) 23 (23.0%) 16 (19.5%) 55 (20.8%) 0.4855 
Angina 6 (6.5%) 6 (6.0%) 6 (7.3%) 8 (3.0%) 0.2841 
Congestive Cardiac failure 10 (10.8%) 14 (14.0%) 6 (7.3%) 13 (4.9%) 0.0254 
Atrial Fibrillation 12 (12.9%) 10 (10.0%) 9 (11.0%) 22 (8.3%) 0.6188 
Ischaemic Heart Disease 24 (25.8%) 28 (28.0%) 16 (19.5%) 39 (14.8%) 0.0145 
Stroke 21 (22.6%) 23 (23.0%) 11 (13.4%) 45 (17.1%) 0.2471 
Deep Vein Thrombosis 3 (3.2%) 0 (0.0%) 0 (0.0%) 2 (0.8%) 0.1311 
Diabetes Mellitus 22 (23.7%) 26 (26.0%) 17 (20.7%) 48 (18.2%) 0.3657 
Depression 44 (47.3%) 42 (42.0%) 36 (43.9%) 109 (41.3%) 0.7805 
Parkinson's disease 9 (9.7%) 4 (4.0%) 3 (3.7%) 9 (3.4%) 0.1239 
Number of comorbidities 4.0 ± 1.4 3.8 ± 1.3 3.8 ± 1.5 3.5 ± 1.5 0.0204 
Data were presented as mean ± SD or n (%). ATC: Anatomical Therapeutic Chemical Classification System; PAS-Cog: Psychogeriatric Assessment 
Scale–Cognitive Impairment. 
 
of dementia showed that using any cardiovascular medications 
during the previous 12 months was associated with lower PAS- 
Cog scores (better cognitive function) and lower probability 
of dementia diagnosis (Table 4). When analysing subgroups 
of cardiovascular medications, cardiac therapy, diuretics, 
beta blocking agents, calcium channel blockers, agents acting 
on the renin-angiotensin system and lipid lowering agents 
were associated with both lower (better) PAS- Cog scores 
and a lower probability of dementia diagnosis (Table 4). 
There were no significant associations between antihyper-
tensive use, peripheral vasodilators and vasoprotective agents 
with PAS-Cog scores or dementia diagnosis (Table 4).  
Multivariable general linear regression models and mul-
tivariable logistic regression models controlling for age, 
gender, hypertension, angina, congestive cardiac failure, 
atrial fibrillation, ischaemic heart disease, stroke, deep vein 
thrombosis, diabetes mellitis, hypercholesterolaemia, de-
pression, Parkinson’s disease and the use of antithrombotic 
agents and antihemorrhagics demonstrated associations that 
were largely consistent with the unadjusted variable regres-
sion models (Figure 1), with the exception of diuretic and 
lipid modifying agents. Following adjustment for these po-
tential confounding factors, the use of diuretic, calcium 
channel blockers, and lipid modifying agents were associ-
ated with lower PAS-Cog scores but were not significantly 
associated with dementia diagnosis (Figure 1). 
4  Discussion 
We found that the use of cardiovascular system medica- 
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Table 3.  Characteristics and comorbidities of study sample by dementia status. 
Characteristic Non-dementia (n = 185) Dementia (n = 348) P value 
Age, yrs 86.0 ± 9.2 85.1 ± 8.1 0.2809 
Female 139 (75.1%) 256 (73.6%) 0.6933 
Any ATC C-class Cardiovascular System Medication 155 (83.8%) 227 (65.2%) < 0.0001 
C01 Cardiac therapy 53 (28.7%) 44 (12.6%) < 0.0001 
C02 Antihypertensives 5 (2.7%) 13 (3.7%) 0.6216 
C03 Diuretics 70 (37.8%) 87 (25.0%) 0.002 
C04 Peripheral vasodilators 1 (0.5%) 3 (0.9%) 0.6882 
C05 Vasoprotectives 7 (3.8%) 8 (2.3%) 0.3237 
C07 Beta blocking agents 64 (34.5%) 52 (14.9%) < 0.0001 
C08 Calcium channel blockers 40 (21.6%) 43 (12.4%) 0.005 
C09 Agents acting on the renin-angiotensin system 97 (52.4%) 102 (29.3%) < 0.0001 
C10 Lipid modifying agents 74 (40.0%) 99 (28.5%) 0.0067 
ATC B-class Anticoagulant Medications   
B01 Antithrombotic agents 47 (25.4%) 57 (16.4%) 0.0123 
B02 Antihemorrhagics 2 (1.1%) 10 (2.9%) 0.2321 
Comorbidities    
Number of comorbidities 4.0 (1.3%) 3.5 (1.4%) < 0.0001 
Hypertension 109 (58.9%) 144 (41.4%) 0.0001 
Angina 14 (7.6%) 12 (3.5%) 0.0356 
Congestive Cardiac failure 24 (13.0%) 18 (5.2%) 0.0015 
Atrial Fibrillation 26 (14.1%) 26 (7.5%) 0.0148 
Ischaemic Heart Disease 46 (24.9%) 60 (17.2%) 0.0358 
Stroke 49 (26.5%) 51 (14.5%) 0.0009 
Deep Vein Thrombosis 3 (1.6%) 2 (0.57%) 0.3472 
Diabetes Mellitus 53 (28.7%) 59 (17.0%) 0.0016 
Hypercholesterolaemia 48 (26.0%) 69 (19.8%) 0.1043 
Depression 88 (47.6%) 142 (40.8%) 0.1334 
Parkinson's Disease 12 (6.5%) 13 (3.7%) 0.1527 
Data were presented as mean ± SD or n (%). ATC: Anatomical Therapeutic Chemical Classification System. 
Table 4.  Unadjusted linear regression and logistic regression on PAS-Cog score and diagnosis of dementia. 
PAS-Cog score Dementia Diagnosis (Yes vs. No) 
Medications on Cardiovascular System 
Coefficient β (95% CI) P value  Odds Ratio (95% CI) P value 
C Any Cardiovascular system medications 4.8 (6.2, 3.4) < 0.0001 0.29 (0.18, 0.47) < 0.0001 
C01 Cardiac therapy 4.0 (5.6, 2.3) < 0.0001 0.41 (0.26, 0.64) < 0.0001 
C02 Antihypertensive 3.7 (7.5, 0.14) 0.0588 1.20 (0.41, 3.5) 0.7432 
C03 Diuretics 3.3 (4.7, 1.9) < 0.0001 0.53 (0.36, 0.77) 0.0009 
C04 Peripheral vasodilators 2.9 (4.6, 10.5) 0.4471 1.6 (0.17, 15.6) 0.6715 
C05 Vasoprotectives 0.17 (4.1, 3.8) 0.9333 0.46 (0.16, 1.3) 0.1339 
C07 Beta blocking agents 3.5 (5.3, 1.9) < 0.0001 0.31 (0.20, 0.47) < 0.0001 
C08 Calcium channel blockers 2.8 (4.6, 1.0) 0.0021 0.55 (0.34, 0.89) 0.0144 
C09 Agents acting on the renin-angiotensin system 4.1 (5.4, 2.8) < 0.0001 0.32 (0.22, 0.46) < 0.0001 
C10 Lipid modifying agents 2.7 (4.1, 1.3) 0.0001  0.56 (0.39, 0.82) 0.0026 
ATC: Anatomical Therapeutic Chemical Classification System, CI: confidence interval, PAS-Cog = Psychogeriatric Assessment Scale-Cognitive Impairment 
 
tions was associated with less cognitive impairment and a 
lower probability of having a dementia diagnosis in a popu-
lation residing in a nursing home for a least one year, who 
had a high prevalence of cardiovascular diseases. Residents 
who had been using cardiovascular system medications over 
a 12-month period were 3.7 (β = 3.7) points lower in  
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Figure 1.  Multivariable linear regression of PASCog score and logistic regression of diagnosis of dementia. All models were adjusted 
for age, gender, antithrombotic agents (ATC code B01), antihemorrhagics (ATC code B02), number of comorbidities and specific comorbid-
ities listed in Table 2. ATC: Anatomical Therapeutic Chemical Classification System; CI: confidence interval; PAS-Cog: Psychogeriatric 
Assessment Scale-Cognitive Impairment. 
PAS-Cog score and 56% (OR = 0.44) less likely to be di-
agnosed with dementia than those who did not use any such 
medications. This association existed for cardiac therapy, 
beta-blockers, and agents acting on the renin-angiotensin 
system as classified by the ATC. 
Similar associations between cardiovascular medication 
use and cognitive status have been reported in other studies. 
An association of reduced cardiovascular medications with 
dementia has been demonstrated in a community setting.[27] 
A similar, but smaller, association of cardiovascular medi-
cation use with better cognitive status within dementia pa-
tients has been shown in an analysis of a Swedish Registry 
data.[28] A three-year prospective cohort study from a Span-
ish register demonstrated that while total pharmaceutical 
consumption increased over the three-year period in people 
with dementia, the consumption of cardiovascular system 
drugs decreased.[29]  
There are several possible explanations for the observed 
association. People living with cognitive impairment or 
dementia are likely to experience barriers to the access and 
prescription of medications for the management of cardio-
vascular disease and its risk factors. People living with cog-
nitive impairment or dementia are less likely to be aware of 
or to effectively communicate their symptoms[30] and may 
also have a lower rate of presentation for investigation of 
symptoms or preventative health management.[31,32] Thus, 
this population may be less likely to receive management 
and prescriptions for non-symptomatic cardiovascular dis-
ease.  
The balance of the benefits and harms of prescribing 
medications to manage cardiovascular risk factors are dif-
ferent in this population to a population without cognitive 
impairment. As dementia is a non-remitting progressive 
condition, associated with a reduced life expectancy for 
many, it may be reasonable that management of risk factors 
that are only likely to lead to a direct impact on health in the 
longer term is reduced.  
However, in some people diagnosed with dementia or 
cognitive impairment there may be instances of under-treat-
ment of cardiovascular symptoms.[33] In a Canadian study, it 
was demonstrated that patients with severe dementia were 
under-treated for stroke and hypertension.[34,35] Additionally, 
optimising prescribing and deprescribing medications for 
people with dementia is complicated by diminished decision 
making capacity and difficulties with comprehension and 
communication by the patient and the lack of clinical prac-
tice guidelines to guide deprescribing for healthcare practi-
tioners; therefore these factors may affect the prescription or 
cessation of medications for management of cardiovascular 
risk factors.[33]  
Limited life expectancy and cognitive impairment are 
important drivers of deprescribing amongst geriatricians.[36] 
Considering reducing or ceasing antihypertensive medica-
tions in frail elderly patients has been recommended, how-
ever patients in the palliative treatment stages of disease 
were excluded from the INSPIRED study.[37,38] Nevertheless, 
if there is inadequate management of cardiovascular disease 
risk factors in some individuals this could lead to greater 
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comorbidities and potentially an increase in any vascular 
component to cognitive impairment.[39] Hence, the decision 
to prescribe cardiovascular medications to residents of 
nursing homes must be balanced against the risk of increas-
ing polypharmacy.[40] In a registry study of people with de-
mentia, there was higher use of drugs to control vascular 
risk factors at baseline in those with non-degenerative vas-
cular dementia.[29]  
There may also be interactions between medications used 
for treating cardiovascular disease and dementia. In the case 
of beta-blockers, there is a known precaution to their use for 
people with dementia prescribed acetylcholinesterase in-
hibitors as a cognitive enhancing agent, due to concerns 
about possible additive bradyarrhythmic events such as 
syncope, bradycardia, arrhythmia and cardiac arrest.[41] In 
addition, centrally acting alpha-blockers, such as prazosin, 
have anticholinergic properties that may worsen neurologi-
cal symptoms in those with cognitive impairment or demen-
tia. No association with cognitive status was seen with the 
class of medicines that includes these medications (anti-
hypertensives, ATC code C02) in this analysis. However, 
the lack of association of the ‘antihypertensive’ group of 
medicines may be because this class also includes anti-adre-
nergics. Anti-adrenergics are considered potentially inap-
propriate for prescription in older adults broadly, rather than 
specifically those with cognitive impairment.[42]  
It is also possible that the observed association is due to a 
lower prevalence of risk factors associated with cardiovas-
cular disease in those with worsening cognition. A cohort 
study of nursing home residents in the United States of 
America found that those with more severe dementia had 
fewer comorbidities, less hypertension and diabetes than 
those with no cognitive impairment.[43] Although the current 
analysis has adjusted for cardiovascular disease and risk 
factor history, our dataset does not capture all possible risk 
factors and it is possible that other confounders which were 
not measured and hence could not be adjusted for (such as 
Body Mass Index or smoking status) may explain the asso-
ciations.  
Finally, as some cardiovascular medications may have a 
cognitive protective effect, those who are taking these 
agents may be less likely to develop dementia. We observed 
better cognitive status and a lower probability of dementia 
associated with taking agents acting on the renin-angio-
tensin system and these agents have been demonstrated to 
prevent cognitive impairment and dementia.[15,17,44] Further-
more, calcium channel blockers were associated with better 
cognitive function in this analysis which is in line with the 
findings of a previous study which showed a longitudinal 
association between calcium channel clockers and a lower 
rate of cognitive decline in very old individuals.[45] Treating 
vascular risk factors may offer a secondary prevention 
strategy towards disease progression in people with demen-
tia.[46] However, further evidence of this is needed before 
encouraging the use of cardiovascular medications in nurs-
ing homes as older people with dementia are already at risk 
of polypharmacy. In the current study, it is not possible to 
determine causation or to examine the direction of any ef-
fect. 
The strengths of the current analysis were the access to 
detailed medication prescribing information for all subjects 
for 12 months from multiple sources. Therefore, the data on 
medication prescribing is considered highly accurate. Tests 
of cognitive function were conducted when no recent cogni-
tive assessment was available and access to a diagnosis of 
dementia from medical records also suggests our measures 
of cognitive status for the individual participants are reliable. 
The participants were from 17 different nursing homes 
across four Australian states. The distributions of the age, 
gender, marital status and type of dementia were similar in 
the INSPIRED study sample to the latest available Austra-
lian population estimates (data not shown) and are therefore 
likely to be representative of Australians living in nursing 
homes nationwide.  
The limitations of the current analysis are those inherent 
to the design of a cross-sectional study; it is not possible to 
know the direction of any effect, i.e. whether cognitive de-
cline, dementia diagnosis, or prescription of cardiovascular 
medications occurred first, thus it is not possible to investi-
gate causality. It is also possible confounders exist which 
have not been adjusted for but that may explain the associa-
tion; although we have adjusted for history of cardiovascu-
lar diseases and risk factors for which data were available. 
As the captured pharmaceutical use data is retrospective, it 
represents medication use in nursing home residents that 
survived for 12 months or longer. Further, although the 
overall sample size for this analysis was relatively large, for 
some subgroups of medications the sample size was small 
which would decrease the statistical power to find associa-
tions with cognitive status. 
In summary, this analysis has demonstrated consistent 
associations between the use of cardiovascular system 
medications and cognitive status among older adults living 
in nursing homes in Australia for 12 months or longer. The 
likely explanation for this cannot be determined, and war-
rants further investigation in longitudinal cohort studies. 
However, this finding may reflect a pattern of reduced ac-
cess to or management of cardiovascular risk disease or its 
risk factors in nursing home residents with worse cognitive 
function.  
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